{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:11:16Z","timestamp":1778735476163,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01378"],"award-info":[{"award-number":["PI20\/01378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR18\/00022"],"award-info":[{"award-number":["JR18\/00022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00027"],"award-info":[{"award-number":["JR21\/00027"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jinf.2024.106291","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T13:56:08Z","timestamp":1729259768000},"page":"106291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis"],"prefix":"10.1016","volume":"89","author":[{"given":"Joan","family":"Mart\u00ednez-Campreci\u00f3s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Zacarias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlete","family":"Nindia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Espinosa-Pereiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Aixut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eugenia","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Jos\u00e9","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sulleiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"T\u00f3rtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez-Montalv\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-7515","authenticated-orcid":false,"given":"Israel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106291_bib1","unstructured":"Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. Available at: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023."},{"issue":"25","key":"10.1016\/j.jinf.2024.106291_bib2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jinf.2024.106291_bib3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2024.106291_bib4","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240007048."},{"issue":"Suppl 1","key":"10.1016\/j.jinf.2024.106291_bib5","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","article-title":"Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"124 Suppl 1","author":"Nasiri","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2024.106291_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/heapol\/czaa147","article-title":"'We had to manage what we had on hand, in whatever way we could': adaptive responses in policy for decentralized drug-resistant tuberculosis care in South Africa","volume":"36","author":"Kielmann","year":"2021","journal-title":"Health Policy Plan"},{"issue":"1","key":"10.1016\/j.jinf.2024.106291_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5588\/ijtld.18.0231","article-title":"Prevalence and risk factors of multidrug-resistant tuberculosis in Cubal, Angola: a prospective cohort study","volume":"23","author":"Aznar","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.jinf.2024.106291_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4269\/ajtmh.19-0175","article-title":"Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in Angola","volume":"101","author":"Aznar","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jinf.2024.106291_bib9","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.jinf.2024.106291_bib10","unstructured":"Special Programme for Research and Training in Tropical Diseases (TDR), Short all-Oral Regimens for Rifampicin-resistant Tuberculosis (ShORRT) Research Package. Available at: \u3008https:\/\/tdr.who.int\/activities\/shorrt-research-package\u3009."},{"key":"10.1016\/j.jinf.2024.106291_bib11","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). Version 26.1 September 2023 [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] \u3008https:\/\/www.meddra.org\u3009 Accessed 10 October 2023."},{"key":"10.1016\/j.jinf.2024.106291_bib12","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, E6 Good Clinical Practice. Available at: \u3008https:\/\/www.ich.org\/page\/efficacy-guidelines\u3009."},{"key":"10.1016\/j.jinf.2024.106291_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2019.04.004","article-title":"Improving attribution of adverse events in oncology clinical trials","volume":"76","author":"George","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jinf.2024.106291_bib14","series-title":"Definitions and Reporting Framework for Tuberculosis","author":"World Health Organization","year":"2013"},{"issue":"3","key":"10.1016\/j.jinf.2024.106291_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis","volume":"55","author":"Abidi","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jinf.2024.106291_bib16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jinf.2024.106291_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jinf.2024.106291_bib18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2024.106291_bib19","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","article-title":"Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens","volume":"71","author":"Kempker","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10362","key":"10.1016\/j.jinf.2024.106291_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2024.106291_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","article-title":"Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis","volume":"111","author":"Fu","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2024.106291_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis","volume":"64","author":"Diacon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10150","key":"10.1016\/j.jinf.2024.106291_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20132017","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jinf.2024.106291_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000818","article-title":"Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective","volume":"3","author":"Rodriguez","year":"2023","journal-title":"PLoS Glob Public Health"},{"issue":"7","key":"10.1016\/j.jinf.2024.106291_bib25","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2024.106291_bib26","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2024.106291_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/medicina58020188","article-title":"MDR tuberculosis treatment","volume":"58","author":"Espinosa-Pereiro","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.jinf.2024.106291_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijid.2021.03.001","article-title":"Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis","volume":"105","author":"Court","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2024.106291_bib29","first-page":"49","article-title":"The value of pragmatic and observational studies in health care and public health","volume":"8","author":"Barnish","year":"2017","journal-title":"Pragmat Obs Res"}],"updated-by":[{"DOI":"10.1016\/j.jinf.2026.106752","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324002251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:44:33Z","timestamp":1778733873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324002251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0163445324002251"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106291","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106291"}}